BioSpace News Archive

Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018

Aviragen intends to reconvene the Special Meeting on February 9, 2018 at 12:00 pm EST.

February 7, 2018

·

7 min read

Bavarian Nordic Announces Positive Results of Pivotal Phase III Study of IMVAMUNE Smallpox Vaccine

In this randomized, open-label study of 440 volunteers, the peak neutralizing antibodies induced by IMVAMUNE were shown to be 2-fold higher than those stimulated by ACAM2000.

February 7, 2018

·

6 min read

BioMidwest

PreventionGenetics Releases Updated Comprehensive Menu of Genetic Tests for Hereditary Cancers

PreventionGenetics has updated their comprehensive menu of tests for a variety of hereditary cancers.

February 7, 2018

·

2 min read

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2018

As of January 31, 2018, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

February 7, 2018

·

1 min read

Drug Development

Follicum Phase IIa Study of FOL-005 Against Hair Loss on Scalp Approved by the German Medicines Agency

Follicum today announced it has received approval from the German Medicines Agency and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on patients with Alopecia.

February 7, 2018

·

1 min read

Planmed Launches Improved Planmed Verity CBCT Scanner

Planmed is proud to present the improved Planmed Verity CBCT scanner – a unique 3D imaging solution for orthopedic as well as head and neck imaging.

February 7, 2018

·

3 min read

Policy

GamaMabs Pharma Receives Orphan Drug Designation From US FDA for Lead Compound GM102

GM102 is a first-in-class monoclonal antibody targeting AMHR2-expressing tumors.

February 7, 2018

·

2 min read

TiGenix: Transparency Information - Feb. 7, 2018

Following the issuance of 413,283 new shares on February 6, 2018 resulting from the exercise of 413,283 warrants of TiGenix NV, the transparency data have changed as follows (status on February 6, 2018):

February 7, 2018

·

3 min read

Allergan Issues Investor FAQ on Federal District C

Deals

Allergan Snaps Up Sydney Biotech for Upfront Payment of US $95M

Elastagen’s revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin.

February 7, 2018

·

4 min read

Drug Development

Synairgen Phase II Clinical Trial Commences Dosing in Patients With COPD

Synairgen today announces that the first patients have been dosed in the Company’s Phase II trial of inhaled SNG001 in patients with chronic obstructive pulmonary disease.

February 7, 2018

·

2 min read